Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-06
2008-08-12
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S293000
Reexamination Certificate
active
07410974
ABSTRACT:
The present invention includes novel compounds of the formula (I) wherein X is absent or trans or cis CHCH, R1is (C1-C10) alkyl unsubstituted or substituted by one to three hydroxy, (C1-C10) alkenyl unsubstituted or substituted by one to three hydroxy, (C1-C10) alkynyl unsubstituted or substituted by one to three hydroxy, or aryl unsubstituted or substituted by one to three hydroxy; R2is hydrogen, alkyl or aryl; R3and R4are, independently of each other, H, halogen, or a solubilizing group, with the provisio that at least one of R3and R4is halogen; and pharmaceutically acceptable salts thereof. The invention also includes pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophylaxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.
REFERENCES:
patent: 3324122 (1967-06-01), Burch
patent: 3542784 (1970-11-01), Burch
patent: 3970648 (1976-07-01), Horn et al.
patent: 3973021 (1976-08-01), Horn et al.
patent: 3974277 (1976-08-01), Horn et al.
patent: 5436233 (1995-07-01), Lee et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 6184377 (2001-02-01), Gao
patent: 6306864 (2001-10-01), Welch, Jr.
patent: 6380204 (2002-04-01), Chenard et al.
patent: 6429311 (2002-08-01), Gao
patent: 6479499 (2002-11-01), Kuo et al.
patent: 2001/0018518 (2001-08-01), Gao
patent: 2002/0025968 (2002-02-01), Pamcku et al.
patent: 2002/0161014 (2002-10-01), Chanchal et al.
patent: 2003/0125344 (2003-07-01), Nagarathnam
patent: 2003/0220357 (2003-11-01), Bankston et al.
patent: 2004/0043987 (2004-03-01), Gouliaev et al.
patent: 2004/0131628 (2004-07-01), Bratzler et al.
patent: 672504 (1966-03-01), None
patent: 2140280 (1972-02-01), None
patent: 1168430 (1969-10-01), None
patent: WO 9834111 (1998-08-01), None
patent: WO 9834115 (1998-08-01), None
patent: WO 01/81346 (2001-11-01), None
patent: WO 03/091224 (2003-11-01), None
patent: WO 2004/004658 (2004-01-01), None
patent: WO 2005/014585 (2005-02-01), None
Burch, Homer A., “Nitrofuryl heterocycles, IV.4-Amino-2-(5-nitro-2-furyl) quinazoline derivatives”Journal of Medicinal Chemistry(1966), 9(3), 408-10.
Cohen, Samuel M. et al., “Comparative carcinogenicity of 5-nitrothiophenes and 5-nitrofurans in rats”Journal of the National Cancer Institute(1976), 57(2), 277-82.
Desos, Patrice et al., “Structure-Activity Relationships in a Series of 2[1H]-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7 Dichloro-2[1H]-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties”Journal of Medicinal Chemistry(1966) 39(1) 197-206.
Gupta, K. “Addressing Antibiotic Resistance”Dis. Mon.(2003) 49(2) 99-110.
Hour, Mann-Jen “6-Alkylamino- and 2,3 Dihydro-3'-methoxy-2-phenyl-4-quinazolinones and Related Compunds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization”Journal of Medicinal Chemistry(2000) 43(23) 4479-4487.
Jiang, Jack B. et al. “Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization”Journal of Medicinal Chemistry(1990) 33(6) 1721-28.
Molina, Enrique et al., “Designing Antibacterial Compounds through a Topological Substructural Approach”Journal of Chemical Information and Computer Sciences(2004), 44(2), 515-521.
Moskalenko, N. Yu et al., “4-Amino-2-styrylquinazolines,— a new class of antiprotozoal drugs”Khimiko-Farmatsevticheskii Zhurnal(1986), 20(4), 437-46.
Nicolle, L.E. “Urinary Tract Infection: Traditional Pharmacologic Therapies” (2003) 49(2) 111-128.
Ogawa, Nobuo et al. “Synthesis and histamine H2-antagonist activity of 4-quinzolinione derivatives”Chemical&Pharmaceutical Bulletin(1988) 36(8) 2955-67.
Van Natta, J.P. et al., “Determination of untreated whole-milk effects on in vitro antibacterial activity”Applied Microbiology(1970), 19(2), 220-23.
Yakhontov, L.N. et al., “Synthesis and Study of Biological Activity of Substituted 4-Amino-2-Styrylquinazolines”Khimiko-Farmatsevticheskii Zhurnal(1975)9(11) 12-18.
Zhikhareva, G.P. et al., “Synthesis and Anti-Inflammatory Activity of Substituted 2-styryl-4-{hacek over (o)}-diethylamino-αmethylbutylamino)-6-nitro and 2-styryl-4-(ó-diethylamino-α-methylbutylamino)-6-aminoquinazolines”Khimiko-Farmatsevtiheskii Zhurnal(1980) 14(2), 45-49.
Zhikhareva, G.P. et al., “Synthesis and Antiviral Activity of Substituted 4-({hacek over (o)}-diethylamino-αmethylbutylamino)-2-styrylquinazolines”Khimiko-Farmatsevticheskii Zhurnal(1978) 12(11) 44-48.
Supplementary European Search Report for Application No. EP 04 76 1630, 2 pages, dated Nov. 11, 2006.
Moskalenko, N. Yu, et al., “4-Amino—styrylquinazolines—a new class of antiprotozoal drugs,”Database Caplus[Online]Chemical Abstracts Service, XP002404560 retrieved from STN, Database accession no. 1987:32975, 2 pages.
Khimiko-Farmatsevticheskii Zhurnal, 20(4), 437-446, Coden: KHFZAN; ISSN: 0023-1134, 1986, XPoo2917813. (See cite No. C8 on Information Disclosure Statement dated Jun. 20, 2006.).
Aicher et al., “Secondary Amides of (R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase,”J. Med. Chem.43:236-249, 2000.
Almansa et al., “Synthesis and Structure—Activity Relationship of a New Series of COX-2 Selective Inhibitors: 1,5-Diarylimidazoles,”J. Med. Chem.46:3463-3475, 2003.
Pagani et al., “Synthesis and in Vitro Anti-MycobacteriumActivity of N-Alkyl-1,2-dihydro-2-thioxo-3-pyridinecarbothioamides. Preliminary Toxicity and Pharmacokinetic Evaluation,”J. Med. Chem.43:199-204, 2000.
Youngman et al., “α-SubstitutedN-(Sulfonamido)alkyl-β-aminotetralins: Potent and Selective Neuropeptide Y Y5 Receptor Antagonists,”J. Med. Chem.43:346-350, 2000.
Chamberland Suzanne
Malouin Francois
Klarquist & Sparkman, LLP
Truong Tamthom N
Ulysses Pharmaceutical Products, Inc.
Wilson James O.
LandOfFree
Halogenated Quinazolinyl nitrofurans as antibacterial agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Halogenated Quinazolinyl nitrofurans as antibacterial agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halogenated Quinazolinyl nitrofurans as antibacterial agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013097